Differentiated approach to treatment of cognitive disorders associated with SARS-CoV-2 (COVID-19), taking into account comorbidity factor

Abstract

The prevalence of cognitive impairment in COVID-19 ranges from 59 to 65 per cent. Such variability may be associated with age and comorbidity. Arterial hypertension, diabetes mellitus, atherosclerosis are the most common comorbid conditions in patients with COVID-19. The cohort of patients with hypertension and diabetes is aged 50 and over, which suggests that age is the most important reason for the difference in the clinical picture of cognitive impairment. To date, there are no clinical guidelines for the management of patients with cognitive impairment and COVID-19, which leads to the use of various drugs, often symptomatic, increasing the risk of polypharmacy. A differentiated approach to therapy should be based on the rule of using drugs with pleiotropic effects and proven effcacy, such as Duzofarm and Nimopin.